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Pompe disease (PD) is a progressive, debilitating 
multisystemic neuromuscular disease. It is often 
fatal if not diagnosed and treated early. It is known 
by several names: acid maltase deficiency; glycogen 
storage disease type II; and glycogenosis type II. All 
muscle groups are affected, viz. skeletal, respiratory and, primarily 
in infants, cardiac muscle.[1,2] There is degeneration of muscle due 
to progressive intracellular accumulation of glycogen as a result 
of deficiency of lysosomal enzyme, acid α-glucosidase (GAA).[1] 
It is an autosomal recessive condition with the GAA gene located 
on chromosome 17q25.[2] The worldwide combined incidence is 
1/40 000, though the infantile form of the disease tends to be more 
common among African-Americans and Chinese people.[2]
PD can present from early infancy into adulthood; it encompasses a 
single disease continuum with variable rates of disease progression. [1,2] 
The severity of the disease is determined by age of onset, organ 
involvement including the degree of severity of muscle involvement 
(skeletal, respiratory and cardiac), and rate of progression.[1,2] In the 
infant under a year, who is a floppy baby in cardiac failure, with 
cardiomegaly, the disease should be suspected. 
Classification
PD is classified into two groups:
• Infantile form: 
• Classic infantile PD is a most severe disease that is rapidly 
progressive and is characterised by prominent cardiomegaly 
with cardiomyopathy, hepatomegaly, muscular weakness and 
hypotonia.[3,4] Death results from cardiorespiratory failure in <1 
year, if not treated.
• Infantile variant form (non-classic in the <1-year group that has 
slower progression and less severe or absent cardiomyopathy).
• Late-onset form:[5] 
• Childhood/juvenile or muscular variant (heterogeneous group) 
presenting later than infancy and typically not including 
cardiomyopathy.
• Adult-onset form characterised by slowly progressive myopathy 
predominantly involving skeletal muscle and presenting as late 
as the 2nd - 6th decade of life.
Diagnosis in South Africa
It is imperative to make an early diagnosis to optimise disease 
management and outcomes. Testing is by way of two separate methods 
performed on the same day and involves: screening for the disease 
via dried blood spot (DBS) sent to Europe; confirmation, requiring 
whole blood samples sent to the National Health Laboratory Service 
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Please refer to the following article for a more detailed 
overview of the comprehensive management of Pompe disease: 
Kishnani PS, Steiner RD, Bali D, et al.; ACMG Work Group 
on Management of Pompe Disease. Pompe disease diagnosis 
and management guideline. Genet Med 2006;8(5):267-288. 
[http://dx.doi.org/10.1097/01.gim.0000218152.87434.f3]
Pompe disease (PD) is an autosomal-recessively inherited neuromuscular disease that, if not diagnosed and treated early, can be fatal. It can 
present from early infancy into adulthood. Due to the lack of acid α-glucosidase, there is progressive intracellular accumulation of glycogen. 
The severity of the disease is determined by age of onset, organ involvement including the degree of severity of muscle involvement, as 
well as rate of progression. PD is classified into two groups: infantile and late-onset, each having two subgroups. The need for two tests 
performed by separate methods (screening and confirmatory) is outlined. It is imperative to try to reduce the time to diagnosis and to 
recognise the possibilities of false-positive results. A multidisciplinary team approach to treatment of affected patients is optimum with, as 
team leader, a physician who has experience in managing this rare disorder. In this article, we present a brief overview of the disease and 
provide guidelines for diagnosis and management of this condition in South Africa. 
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(NHLS) in Johannesburg, South Africa, for GAA enzyme assay in 
lymphocytes, with absent or markedly reduced GAA enzyme activity 
offering a conclusive diagnosis.
Fibroblasts obtained from a skin biopsy may also be tested for 
GAA, but a limiting factor is that the time to diagnosis is 4 - 6 weeks. 
A muscle biopsy may be confirmatory, but limiting factors are that it 
requires general anaesthesia, which can have a fatal outcome. Tissue 
samples must be frozen and shipped to the USA for analysis. Genetic 
studies may be performed in the USA or Europe, if required.
Screening
• Whole blood onto four spots on the DBS card – after DBS is dry 
and all details are provided on the card, it can be sent to Europe 
for analysis.
• If infantile-onset PD is suspected, urgent testing should be 
requested.
Confirmation
• Arrange courier to be available through a local laboratory.
• Draw whole blood (3 - 5 ml into an acid citrate dextrose (ACD) 
tube), preferably in the early morning. Samples should include 
blood from:
• patient 
• control: unrelated donor (e.g. doctor, nurse, lab technician).
• Wrap both tubes in tissue paper and place on an ice-brick in a 
polystyrene container (do not freeze).
• Specimens should be delivered to the NHLS within three hours of 
the sample being drawn (i.e. before midday).
• It is advisable to inform the NHLS lab technician to expect samples 
– this will facilitate quicker transit to the lab from the NHLS 
reception.
• It is preferable not to test on a Friday as there is a huge risk of 
samples being unattended, resulting in higher false-positive results.
• Results are usually available within 7 - 10 working days.
A positive diagnosis of PD is made when both the screening and 
confirmatory tests corroborate each other.
Management
As this is a multisystem disorder, management requires 
a multidisciplinary team led by a physician with experience in 
managing this disorder. The team comprises a:




• neurologist, neuromuscular specialist, physical therapist, 





Due to overall hypotonia and respiratory muscle weakness, patients 
are at high risk for pneumonia, leading to respiratory failure 
requiring ventilatory support; there may be ventilator dependence 
and even death.[5] There should be a low threshold to treat infections. 
Immunisations are required, including: seasonal influenza vaccine 
for patients and household members; pneumococcal vaccine; 
palivizumab is recommended during respiratory syncytial virus 
(RSV) season in infants and young children and older patients who 
have not received these immunisations (for which special motivation 
to the medical funders may be required).
General anaesthesia[5] must be performed by someone familiar 
with anaesthesia in PD patients as ‘routine’ drugs may result in 
a fatality, and surgical procedures must be grouped for a single 
anaesthetic where possible.
Since the end of 2012, enzyme replacement therapy (ERT) (as 
alglucosidase alfa) has been registered with the Medicines Control 
Council in South Africa for use in PD patients. Patients with infantile-
onset PD who receive ERT have significantly prolonged survival, 
decreased cardiomegaly, and improved cardiac and skeletal muscle 
function. The cardiac response appears to be good irrespective of 
the stage of disease at initiation of ERT, while the skeletal muscle 
response appears more variable than cardiac muscle. The best skeletal 
muscle response occurs when ERT is administered prior to skeletal 
muscle damage.[6,7] 
Treatment with alglucosidase alfa in late-onset PD is associated with 
improved walking distance and stabilisation of pulmonary function.[8]
Alglucosidase alfa is available in 50 mg dried powder vials. There 
are specific guidelines to ensure proper reconstitution of the solution. 
The infusions are performed every 2 weeks (dosage 20 mg/kg) in an 
environment with correct observation of vital signs and equipment 
available for full resuscitation.
Infusion-associated reactions (IARs) occur in ~50% of patients 
treated with alglucosidase alfa. IARs occur at any time during, and 
mostly up to two hours after, the infusion of alglucosidase alfa, and 
are more likely with higher infusion rates. Patients may be pre-treated 
with antihistamines, antipyretics and/or steroids. The prescribing 
information should be consulted before administration. Patients can 
eventually receive their infusions in a home-based environment.
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